Grail, a cancer detection company, has completed its spin-off from Illumina and started trading on Nasdaq. Grail aims to reduce the global burden of cancer through innovative screening technologies. Despite falling shares on debut, Grail is focused on early cancer detection.
Grail CEO Bob Ragusa told STAT: "Adding Galleri to standard of care screening creates a powerful and efficient cancer screening system." https://t.co/Sk73bHBxOA
StockWatch: "Final Resolution" Set for Illumina's Grail Saga Illumina’s long saga over its acquisition of Grail will end this week, when the sequencing giant spins off the cancer blood test developer. Read more: https://t.co/7vT9ckjjCu https://t.co/w75KLdGx9S
Multi-cancer detection tests could be losing their luster, judging by Grail's lurching start as a newly public company and others taking a cancer-by-cancer approach. https://t.co/auBZM2Uruj
Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble https://t.co/amA2hRNF4n #biotech #news
Spun out of @illumina (for the second time), @GrailBio continues its pursuit of FDA approval & broader reimbursement for #liquidbiopsy #cancer test #Galleri. In $GRAL's first day trading, shares closed at $17 each, down 8.75% from the opening price. https://t.co/7EKaaESP6F $ILMN
Illumina Spin-Off Now Complete, Grail Sets Out on Its Own on the Public Markets https://t.co/0LgTuj1wCp
Grail's shares fall in Nasdaq debut after spin-off from Illumina https://t.co/vFUqTMf4Dd https://t.co/xffa67EFzf
🎊 Join us in welcoming @GrailBio to the #NasdaqListed family! 👏 $GRAL is working to change the trajectory of cancer mortality and transform cancer screening through innovative technologies. #healthcare #cancer https://t.co/y4ncOg4Hcf
Shares of Grail fell as much as 13.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina . https://t.co/Jf8ZzCNstj https://t.co/Jf8ZzCNstj
Grail to Begin Trading on Nasdaq as Illumina Completes Divestiture https://t.co/hTO6piwP4F #biotech #news
Bay Area early cancer detection company Grail goes public after spinning out from Illumina — again https://t.co/3mi9ytjxpC
Shares of Grail fell as much as 11.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina . https://t.co/cXMfpNrut5 https://t.co/cXMfpNrut5
Illumina spinoff Grail going public today on the Nasdaq. Grail CEO joined us ahead of the opening trade to talk early cancer detection and its testing products. https://t.co/dbTCy5ynJU
$GRAL Grail to begin trading as $ILMN Illumina completes spinoff - SA https://t.co/jdSnW4GjbQ
Listing today on @NasdaqExchange, @GrailBio is focused on reducing the global burden of cancer through innovative multi-cancer screening technologies. Congratulations, $GRAL team! https://t.co/YW6KZWGCf6
Grail bets big on flagship cancer test after spin-off from Illumina https://t.co/R3OU0NrXWb https://t.co/R3OU0NrXWb
Illumina parts ways with Grail, with divestiture complete https://t.co/KjRqohmXgk #biotech #news